Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8491 to 8505 of 8992 results

  1. Elotuzumab for untreated multiple myeloma [ID966]

    Discontinued Reference number: GID-TA10134

    Technology appraisal guidance
    Discontinued

  2. Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer [ID1495]

    Discontinued Reference number: GID-TA10395

    Technology appraisal guidance
    Discontinued

  3. Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation [ID1582]

    Discontinued Reference number: GID-TA10495

    Technology appraisal guidance
    Discontinued

  4. Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]

    Discontinued Reference number: GID-TA10254

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545

    Discontinued Reference number: GID-TA10418

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer [ID1509]

    Discontinued Reference number: GID-TA10413

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued Reference number: GID-TA10244

    Technology appraisal guidance
    Discontinued

  8. Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

    Discontinued Reference number: GID-TA10154

    Technology appraisal guidance
    Discontinued

  9. Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

    In development Reference number: GID-TA10899 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

    In development Reference number: GID-TA10696 Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

    In development Reference number: GID-TA11759 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women [ID1307]

    In development Reference number: GID-TA10261 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [ID6551]

    In development Reference number: GID-TA11690 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Digital technologies for multidisciplinary weight management

    In development Reference number: GID-HTE10077 Expected publication date: TBC

    Health technology evaluations
    In development

  15. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

    Technology appraisal guidance
    In development